UNSPSC 51433304: Flavodilol maleate

This classification denotes an antihypertensive agent with the molecular formula C21H23NO4.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0DFC0D3Q8, chemically known as 4h-1-benzopyran-4-one, 7-(2-hydroxy-3-(propylamino)propoxy)-2-phenyl-, (+-)-, (z)-2-butenedioate (1:1) (salt) but generally known as flavodilol maleate, which bears US NIH Compound Identifier 6435382. Most nations schedule flavodilol maleate under HS 29329985 and SITC 51569. As of Q4 2014, FLAVODILOL MALEATE remains the US FDA Preferred Term for this commodity.

SMILES: CCCNCC(COC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3)O.C(=CC(=O)O)C(=O)O.

UNSPSC 51433304 Flavodilol maleate, a Commodity code, represents a narrow pharmaceutical ingredient tier within state and local procurement activity, though recent opportunities under this specific code are sparse. State and local governments procure medications and pharmaceutical products through this taxonomy primarily for emergency medical services, public health agencies, and cooperative purchasing alliances serving multiple jurisdictions. The actual buying activity visible in recent solicitations spans advanced life support medications (epinephrine, adenosine, labetalol, diltiazem), generic multi-source pharmaceuticals distributed through authorized wholesalers, and direct-to-manufacturer prescription programs. Issuing bodies include municipal fire-rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across state agencies and local government facilities.

Activity is geographically dispersed across Florida, Texas, Minnesota, and Oregon, with the most concrete recent opportunity being the City of Tampa Fire Rescue's sealed-bid procurement (IFB 26P00188, due April 8, 2026, estimated value $40,000) for advanced life support medications with a one-year term and renewal options, featuring a Small Local Business Enterprise sheltered market with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers effective July 1, 2026, with evaluations weighted 75 percent on price competitiveness and the remainder on compliance, EDI capability, and administrative fee adherence. The Texas Health and Human Services Commission simultaneously issued an RFI (HHS0017013, posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs before issuing formal RFPs, indicating preliminary-stage state procurement strategy development rather than immediate contracting volume.